Search clinical trials for: Baricitinib Oral Tablet

Total 13784 results

Galapagos NV

Terminated

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Healthy

Netherlands
Shionogi
QuatRx Pharmaceuticals

Completed

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Atrophy | Vaginal Diseases
Fabrizio Cantini

Completed

Baricitinib Therapy in COVID-19

Pneumonia | COVID

Italy
Galapagos NV
PRA Health Sciences

Completed

Bioavailability Study With GLPG1972

Osteoarthritis

Netherlands
University of Erlangen-Nürnberg Medical School
Bayer

Recruiting

Finerenone and Renal Oxidative Stress

Type2diabetes

Germany
Istituto Oncologico Veneto IRCCS

Completed

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Glioblastoma Multiforme

Italy
Rochester Center for Behavioral Medicine

Active, not recruiting

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Chronic Fatigue Syndrome | Myalgic Encephalomyelitis

United States
Oscotec Inc.

Completed

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

United States, Greece, Korea, Republic of, Poland, Spain
Aminex Therapeutics, Inc.
Iqvia Pty Ltd; Novella Clinical

Withdrawn

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

Neoplasms | Tolerance | Medication Toxicity

United States
Pfizer

Completed

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Duke University
Eli Lilly and Company; National Institute on Minority Health and Health Disparities...

Recruiting

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE)

Chronic Kidney Diseases

United States
Eli Lilly and Company

Active, not recruiting

A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Aicardi Goutieres Syndrome | Nakajo-Nishimura Syndrome | Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome | STING-Associated Vasculopathy With Onset in Infancy

Japan
Wright State Physicians

Completed

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Allergic Contact Dermatitis

United States
University Hospital, Brest
Eli Lilly and Company

Completed

BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR)

Polymyalgia Rheumatic (PMR)

France
University Hospital of Patras

Completed

Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

COVID-19

Greece
Eli Lilly and Company
Incyte Corporation

Terminated

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD6)

Atopic Dermatitis

United States, Puerto Rico, Canada
Eli Lilly and Company

Completed

A Study of Baricitinib in Healthy Japanese Participants

Healthy Participants

Japan
Eurofarma Laboratorios S.A.

Completed

A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia (LAILAII)

Lactose Intolerance

Brazil
Al-Azhar University

Not yet recruiting

Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE) (PE)

Premature Ejaculation
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

Healthy

United States
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
The Mind Research Network

Terminated

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

Tobacco Smoking | Alcohol Use Disorder

United States
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)

COVID-19

United States, Spain, India, Germany, Puerto Rico, Brazil, Korea, Republic of, Argentina, Italy, Japan, Mexico, Russian Federation, United Kingdom
Eli Lilly and Company
Incyte Corporation

Completed

Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD2)

Atopic Dermatitis

Spain, Australia, Switzerland, Israel, Korea, Republic of, Japan, Poland, Argentina, Austria, Hungary
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Spain, Taiwan, France, Japan, Mexico, Puerto Rico, Austria, Poland, Korea, Republic of, Argentina, Romania
Eli Lilly and Company

Completed

A Study of LY3009104(Baricitinib) for Healthy Subjects

Healthy Volunteer

United States
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

Healthy

China
Eli Lilly and Company

No longer available

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE) | Juvenile Dermatomyositis (JDM) | Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI) | Aicardi-Goutières Syndrome (AGS)

United States, United Kingdom
Centre Antoine Lacassagne

Recruiting

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) (CALHYS)

HER2 Negative Breast Cancer Not Immediately Operated

France
Paul Beringer
Paratek Pharmaceuticals Inc

Completed

Pharmacokinetics of Omadacycline in Cystic Fibrosis

Cystic Fibrosis

United States
Global Alliance for TB Drug Development

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

Tuberculosis | Tuberculosis, Pulmonary

United States
Tang-Du Hospital

Not yet recruiting

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Traumatic Brain Injury

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura

China
University of North Carolina, Chapel Hill
Bayer

Recruiting

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

Kidney Transplant; Complications

United States
Paratek Pharmaceuticals Inc

Recruiting

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

Bacterial Infections

United States
Axsome Therapeutics, Inc.

Completed

Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

Obstructive Sleep Apnea | Narcolepsy | Postpartum | Excessive Sleepiness | Excessive Daytime Somnolence

United States
St. Petersburg State Pavlov Medical University
Ministry of Health, Russian Federation

Completed

Ruxolitinib for Steroid-refractory GVHD

Graft Vs Host Disease

Russian Federation
Bangabandhu Sheikh Mujib Medical University, Dhaka...
Healthcare Pharmaceuticals

Recruiting

Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

Spondyloarthritis, Axial

Bangladesh
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Healthy

Belgium
Galapagos NV

Completed

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

Healthy

Belgium
Prof. Dr. Umar Farooq
Ayub Medical College, Abbottabad

Unknown

Effectiveness of Hydroxychloroquine in Covid-19 Patients (Covid)

COVID19

Pakistan
Jacob Pontoppidan Thyssen
The Novo Nordic Foundation

Recruiting

Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)

Chronic Hand Eczema

Denmark
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Aclaris Therapeutics, Inc.

Terminated

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Psoriatic Arthritis

United States, Poland
Aclaris Therapeutics, Inc.

Completed

ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

United States
Oslo University Hospital
Göteborg University; Sahlgrenska University Hospital, Sweden

Completed

Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage

Norway
Hospital Universitario Ramon y Cajal

Unknown

Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH)

Cardiogenic Shock

Spain
AngioLab, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

Nonalcoholic Steatohepatitis

Korea, Republic of
Irish Response t/a Lifes2good
Stephens & Associates, Inc.

Completed

To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair

Hair Thinning

United States
Assiut University

Not yet recruiting

Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo

Vitiligo, Generalized

Search clinical trials for: Baricitinib Oral Tablet

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations